While some studies did not show quantitative differences in IGF2 expression in CRC patients with T2DM, compared to those not affected by diabetes [75], newer research report that upregulation of DOK5, IGF2, and IRS2 in colorectal cancer and T2DM patients is associated with significantly decreased overall survival (OS) [73]. This evidence concerns the gene IGF2 and colorectal carcinoma.